Condition (MeSH)
Myositis Ossificans
ClinicalTrials.gov lists 23 trials for Myositis Ossificans or a narrower condition beneath it. Clementia Pharmaceuticals Inc. has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
23 of the 23 trials are tagged with Myositis Ossificans itself; the rest are tagged with a narrower condition beneath it.
When did Myositis Ossificans trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 2 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Myositis Ossificans trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Observational | 7 |
| Expanded access | 1 |
How many Myositis Ossificans trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Completed | 12 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Myositis Ossificans trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Clementia Pharmaceuticals Inc. | 7 |
| Regeneron Pharmaceuticals | 5 |
| Ipsen | 3 |
| Incyte Corporation | 2 |
| Ashibio Inc | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Myositis Ossificans? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Palovarotene | 5 |
| Garetosmab | 3 |
| Andecaliximab | 1 |
| AZD0530 Difumarate | 1 |
| IPN60130 | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| INCB000928 | 2 |
| Palovarotene dose level 1 | 1 |
| D. Midazolam | 1 |
| Palovarotene dose level 4 | 1 |
| Palovarotene dose level 3 | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Myositis Ossificans trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Epiphyses Premature Fusion | 21 | 1 |
| Corona virus infection | 18 | 2 |
| Pneumonia | 12 | 4 |
| Condition aggravated | 8 | 3 |
| Exposure to communicable disease | 7 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Myositis Ossificans? (31)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 31 publications.
Prevalence (14)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Fibrodysplasia ossificans progressiva | Point prevalence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Fibrodysplasia ossificans progressiva | Point prevalence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Fibrodysplasia ossificans progressiva | Point prevalence | <1 / 1 000 000 | United States | US | Exact |
| Fibrodysplasia ossificans progressiva | Point prevalence | <1 / 1 000 000 | United States | US | Exact |
| Fibrodysplasia ossificans progressiva | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 14 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Fibrodysplasia ossificans progressiva | 337 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Fibrodysplasia ossificans progressiva | 337 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.